The terms defined in this section will, for the purposes of this Agreement, have the meanings specified as follows:

(a) “Applicable Beneficiary” has the meaning given such term in 42 CFR § 423.100.

(b) “Applicable Discount” means

i. for a plan year 2011 to 2018, fifty percent, or
ii. with respect to a plan year after 2018, seventy percent of the negotiated price (as defined in section I(m) of this agreement), of the applicable drug of a Manufacturer that falls within the coverage gap (as defined in section I(e) of this agreement) and that remains after the negotiated price is reduced by any Part D supplemental benefits that are available.

(c) “Applicable Drug” has the meaning given such term in section 1860D-14A(g)(2)(A) of the Act.

(d) “Centers for Medicare & Medicaid Services (CMS)” means the agency of the Department of Health and Human Services having the delegated authority to operate the Medicare program.

(e) “Coverage Gap” has the meaning set forth in 42 CFR § 423.100.

(f) “Covered Part D drug” has the meaning as set forth in 42 CFR § 423.100.

(g) “Date of Dispensing” means the date of service.

(h) “Discount Program” means the Medicare Coverage Gap Discount Program established under section 1860D-14A of the Act.

(i) “Labeler Code” has the meaning set forth in 42 CFR § 423.2305.

(j) “Manufacturer” has the meaning given such term in 42 CFR § 423.2305.

(k) “Medicare Part D Discount Information” has the meaning given such term in 42 CFR § 423.2305. The Medicare Part D Discount Information data elements are set forth in Exhibit A of this Agreement.

(l) “National Drug Code (NDC)” has the meaning given such term in 42 CFR § 423.2305. For the purposes of this Agreement, unless otherwise specified, the NDC refers to the 11-digit (inclusive of 5 digit labeler code, 4 digit product code, and 2 digit package size code) NDC.

(m) “Negotiated Price” has the meaning given such term in 42 CFR § 423.2305.
(n) “Part D drug” has the meaning given such term in 42 CFR § 423.100.
(o) “Part D plan” has the meaning given such term in section 42 CFR § 423.4.
(p) “Part D Sponsor” has the meaning given such term in section 42 CFR § 423.4.
(q) “Part D Supplemental benefits” has the meaning given such term in 42 CFR § 423.100.
(r) “Prescription Drug Event (PDE)” refers to a summary record that documents the final adjudication of a Part D dispensing event.
(s) “Qualified Retiree Prescription Drug Plan” has the meaning given such term in section 1860D-22(a)(2) of the Act.
(t) “Secretary” means the Secretary of the United States Department of Health and Human Services, or any successor thereto, or any officer or employee of the Department of Health and Human Services or successor agency to whom the authority to implement this Agreement has been delegated.
(u) “Third Party Administrator (TPA)” has the meaning given such term in 42 CFR § 423.2305.

II. MANUFACTURER’S RESPONSIBILITIES

In order for Part D coverage to be available for applicable drugs of a Manufacturer, the Manufacturer agrees to the following:

(a) All the applicable requirements and conditions set forth in sections 1860D-14A through 1860D-43 of the Act, in 42 CFR Part 423, and general instructions.

(b) To reimburse all applicable discounts provided by Part D sponsors on behalf of the Manufacturer for all applicable drugs having NDCs with the Manufacturer’s FDA-assigned labeler code(s) invoiced to the Manufacturer as specified in 42 CFR § 423.2315(b)(2) and through general instructions.
(c) To pay each Part D sponsor within 38 calendar days of receipt from the TPA of the electronic invoice and Medicare Part D Discount Information for the applicable discounts included on the invoice, except as specified in 42 CFR § 423.2330(c)(3). The invoice will be calculated by CMS (or the TPA) based upon PDE information reported to CMS by such Part D sponsor during the specified quarter, which may include PDEs with dates of service from prior quarters. Receipt of the invoice shall be considered to be one (1) calendar day after the TPA electronically transmits the invoice to the Manufacturer or otherwise notifies the Manufacturer that it is available (e.g., it is posted on a secure web site for download).

(d) To provide CMS with all labeler codes for all the manufacturer’s applicable drugs and to promptly update such list with any additional labeler codes for applicable drugs as described in section I(c).

(e) To collect, have available, and maintain appropriate data, including data related to Manufacturer’s labeler codes, FDA drug approvals, FDA NDC Directory listings, NDC last lot expiration dates, utilization and pricing information relied on by the Manufacturer to dispute invoices, and any other data CMS determines are necessary to carry out the Discount Program, for a period of not less than 10 years from the date of payment of the invoice as described in 42 CFR § 423.2315(b)(5).

(f) To comply with conditions in sections 1860D-14A and 1860D-43 of the Act as interpreted and applied by this Agreement and any changes to the Medicare statute that affect the Discount Program.

(g) To comply with the requirements imposed by CMS for purposes of administering the Discount Program.
(h) To pay all applicable discounts provided by Part D sponsors on behalf of the Manufacturer for all applicable drugs having NDCs with the Manufacturer’s FDA-assigned labeler code(s) for applicable dates of service except for those dates of service after the marketing end date, which is the last lot expiration date, specified in a product’s structured product labeling electronically submitted to the FDA, if such marketing end date was submitted to the FDA prior to such date.

(i) To submit to periodic audits of data and documentation referenced in sections II (e) and V (d) of this Agreement and as described in 42 CFR § 423.2330. Such notice shall include a description of the scope of the audit and shall be reasonably tailored to the specific purpose of the audit.

(j) To comply with the audit and dispute resolution requirements described in section V of this Agreement and 42 CFR § 423.2330 as described in 42 CFR § 423.2315(b)(6).

(k) To comply with the confidentiality requirements set forth in section VI of this Agreement.

(l) To electronically list and maintain an up-to-date electronic FDA listings of all NDCs of the Manufacturer, including providing information about discontinued drugs to enable the publication of accurate information regarding what drugs, identified by NDC, are in current distribution as described in 42 CFR § 423.2315(b)(7).

(m) To maintain up-to-date NDC listings with the electronic database vendors to which the manufacturer provides NDCs for pharmacy claims processing as described in 42 CFR § 423.2315(b)(8).

(n) To enter into and have in effect, under terms and conditions specified by CMS, an agreement with the TPA as described in 42 CFR § 423.2315(b)(9).

(o) To pay quarterly invoices directly to accounts established by Part D sponsors via electronic funds transfer, or other manner if specified by CMS, within the time period specified in
subsection (c) of this section and to provide the TPA with electronic documentation of such payment in a manner specified by CMS as described in 42 CFR § 423.2315(b)(10).

(p) To use information disclosed to the Manufacturer on the invoice, as part of the Medicare Part D Discount Information, or upon audit or dispute only for purposes of paying the discount under the Discount Program as described in 42 CFR § 423.2315(b)(11).

(q) The Manufacturer’s full compliance with the responsibilities listed in this Section II shall constitute satisfaction of the Manufacturer’s responsibilities under the Discount Program. Reliance on the information in the invoice shall satisfy any obligation of the Manufacturer to determine the amount of money to pay to any Part D sponsor under this Agreement or section 1860D-14A or other relevant statutes.

III. SECRETARY’S RESPONSIBILITIES

(a) The Secretary shall require Part D sponsors to make applicable discounts available to applicable beneficiaries at the pharmacy, by mail order service, or at any other point-of-sale for applicable drugs beginning January 1, 2020. The Secretary shall also require Part D sponsors to make applicable discounts available to applicable beneficiaries after the point-of-sale if it is later determined that a drug dispensed to a beneficiary was an applicable drug dispensed to an applicable beneficiary.

(b) The Secretary is responsible for monitoring compliance by the Manufacturer with the terms of this Agreement and with monitoring compliance by Part D sponsors and the TPA with their respective obligations in connection with the Discount Program.

(c) The Secretary is responsible for collecting PDE information from Part D sponsors for monitoring and tracking the applicable discounts provided by Part D sponsors and reimbursed by
Manufacturers for applicable drugs, and for implementing internal control measures designed to ensure the accuracy and appropriateness of discount payments provided by Part D sponsors.

(d) In accordance with section V of this Agreement and as described in 42 CFR § 423.2330, the Secretary may audit the Manufacturer periodically with respect to the Manufacturer's labeler codes, NDC last lot expiration dates, utilization and pricing information relied on by the Manufacturer to dispute quarterly invoices, and any other data the Secretary determines are necessary to carry out the Discount Program.

(e) The Secretary shall directly or through a contract with one or more third parties (the TPA):

1. Receive and transmit information, including Medicare Part D Discount Information among the Secretary, Manufacturer, Part D sponsors and other individuals or entities the Secretary determines appropriate;

2. Receive, distribute, or facilitate the distribution of funds of the Manufacturer to appropriate individuals or entities;

3. Provide adequate and timely information to the Manufacturer as necessary for the Manufacturer to fulfill its obligations under this Agreement;

4. Calculate the invoice and reconcile any discrepancies with applicable discounts reported by Part D sponsors prior to invoicing Manufacturers;

5. Notify the Manufacturer of invoice errors or retroactive adjustments and make any necessary adjustments to subsequent invoices;

6. Permit manufacturers to conduct periodic audits, directly or through contracts, of the data and information used to determine the applicable discounts for applicable drugs of the Manufacturer under the Discount Program in accordance with section V of this Agreement.
(f) The Secretary shall not disclose any identifying beneficiary information in these reports or otherwise under this Discount Program except as may be required by a court with competent jurisdiction.

(g) The Secretary shall be the sole source of information regarding beneficiary eligibility to receive the applicable discount and the Secretary’s determination regarding beneficiary eligibility is not subject to audit or dispute by Manufacturer.

(h) The Secretary shall make public a list of Manufacturers and their reported labeler codes that are subject to an existing Discount Program Agreement.

(i) The Secretary shall ensure that adjustments are made to invoices as a result of any information obtained relating to errors, including information obtained as a result of the Secretary’s audit of a Part D sponsor or the TPA or an audit of data and information made available by the TPA as specified in section V performed by a Manufacturer. In the event a systemic error is discovered, the Secretary shall ensure that either CMS or the TPA identify all invoices affected by the error, notify the Manufacturer and determine the impact of the error on invoiced discounts, and adjust the invoices of the affected Manufacturers (or implement an alternative reimbursement process if determined necessary by the Secretary) to correct any underpayment or overpayment that was requested on prior invoices.

IV. PENALTY PROVISIONS

(a) The Secretary shall impose a civil monetary penalty on a Manufacturer that fails to pay applicable discounts under the Agreement and as described in 42 CFR § 423.2340. For purposes of this Agreement, the Manufacturer will have failed to pay applicable discounts if payment has not been transmitted within 38 calendar days of receipt of the applicable invoice for each
identified Part D sponsor. The amount for each such failure is the amount the Secretary determines is commensurate with the sum of the amount that the Manufacturer would have paid with respect to such discounts under the Agreement, which will then be used to pay the applicable discounts which the Manufacturer failed to provide, plus an additional 25 percent of the amount the Manufacturer would have paid with respect to such discounts under the agreement.

(b) The provisions of section 1128A of the Act (other than subsections (a) and (b)) shall apply to a civil monetary penalty in the same manner as such provisions apply to a penalty or proceeding under section 1128A(a) of the Act.

(c) In the event that a Manufacturer declares bankruptcy, as described in Title 11 of the United States Code, and as a result of the bankruptcy, fails to pay the total sum of civil monetary penalties imposed, the Secretary files a proof of claim with the bankruptcy court to recover the unpaid amount of the civil monetary penalties imposed on the Manufacturer.

V. AUDIT AND DISPUTE RESOLUTION

(a) Both parties shall have the right to conduct periodic audits as specified in this section V of this Agreement and as described in 42 CFR § 423.2330, directly or through third parties. Periodic shall mean no more often than annual.

(b) The party requesting the audit shall provide the other party with sixty (60) days notice of the reasonable basis for the audit and a description of the information required for the audit as described in 42 CFR § 423.2330. The TPA will determine an audit schedule for Manufacturers based upon available resources.

(c) The Manufacturer shall have the right to audit the data and information (specified in Exhibit B) for a statistically significant sample size of PDEs used to determine the applicable discounts
for applicable drugs having NDCs with the Manufacturer’s FDA-assigned labeler code(s) under
the Discount Program as described in 42 CFR § 423.2330(a)(3). The Manufacturer is limited to
auditing the data and information made available by the TPA and is not permitted to audit CMS
records or the records of Part D sponsors. The TPA will make such data and information
available on-site and, with the exception of work papers, such information cannot be removed
from the audit site. The auditor is further limited to releasing only an opinion of the results of
the audit and cannot release any other information obtained from the audit, including its work
papers, to its client, employer or any other party as described in 42 CFR § 423.2330(a)(4).
(d) The Secretary, as described in 42 CFR § 423.2330(b), shall have the right to audit
appropriate data, including data related to Manufacturer’s labeler codes, NDC last lot expiration
dates, utilization and pricing information relied on by the Manufacturer to dispute quarterly
invoices and, any other data the Secretary determines are necessary to carry out the Discount
Program.
(e) In the event that a Manufacturer disputes a quarterly invoice, the Medicare Part D Discount
Information provided by the TPA with the quarterly invoice, or raises other issues arising under
the Agreement, the Manufacturer shall provide written notice of the issue or dispute to the TPA
within 60 days of receipt of the information that is the subject of the dispute. Such notice shall
be accompanied by supporting evidence that is material, specific, and related to the dispute or
issue, as described in 42 CFR § 423.2330(c)(1) and (2).
(f) The Manufacturer shall not withhold any invoiced discount payments pending dispute
resolution with the sole exception of invoiced amounts for applicable drugs having NDCs not
specified as being subject to the Agreement, as described in 42 CFR § 423.2330(c)(3). If
payment is withheld to dispute that an NDC is subject to the Agreement, the Manufacturer shall
notify the TPA and applicable Part D sponsors that payment is being withheld for this reason within 38 calendar days of receipt of the applicable invoice.

(g) Manufacturer disputes and appeals will be conducted in accordance with 42 CFR § 423.2330(c)(4). If the Manufacturer receives an unfavorable determination from the TPA or the dispute is not resolved within 60 calendar days of the TPA’s receipt of notice of the dispute, the manufacturer may request an independent review and determination by an entity specified by CMS. A request for independent review must be made within 30 calendar days of the Manufacturer’s receipt of an unfavorable determination from the TPA, or 90 calendar days after the TPA’s receipt of notice of the dispute if the Manufacturer and TPA cannot resolve the dispute within 60 calendar days, whichever is earlier. If the Manufacturer receives an unfavorable determination from independent review entity, the Manufacturer may request review by the CMS Administrator within 30 calendar days of receipt of notification of such determination. The decision by the CMS Administrator is final and binding.

(h) As set forth in 42 CFR § 423.2330(c)(7), CMS adjusts future invoices (or implement an alternative reimbursement process if determined necessary by CMS) if the dispute is resolved in favor of the Manufacturer.

VI. CONFIDENTIALITY PROVISIONS

(a) Any confidential information disclosed by the Manufacturer in connection with this Agreement will not be disclosed by the Secretary in a form that identifies the Manufacturer, except as necessary to carry out provisions of section 1860D-14A of the Act or otherwise
required by law. This restriction does not limit the Office of Inspector General’s authority to fulfill the Inspector General’s responsibilities in accordance with applicable Federal law.

(b) Information disclosed to the Manufacturer pursuant to this Agreement shall only be used for purposes of paying the discount under the Discount Program in accordance with the provisions set forth in section VII of this Agreement. CMS or the TPA will disclose to the Manufacturer only the minimum data necessary for the Manufacturer to fulfill its obligations under this Agreement.

(c) Except where otherwise specified in the Act or Agreement, the Manufacturer will observe applicable State confidentiality statutes, regulations and other applicable confidentiality requirements.

(d) Notwithstanding the nonrenewal or termination of this Agreement for any reason, the confidentiality provisions of this Agreement will remain in full force and effect with respect to information disclosed under this Agreement prior to such nonrenewal or termination.

VII. DATA USE PROVISIONS

The Data Use provisions set forth in Exhibit C of this Agreement govern the use of data CMS provides to the Manufacturer either directly or through the TPA for purposes of the administration of the Discount Program pursuant to sections 1860D-14A and 1860D-43 of the Act.

VIII. NONRENEWAL AND TERMINATION

(a) Unless otherwise terminated by either party pursuant to the terms of this Agreement, the Agreement shall be effective for an initial period of 24 months from the January 1 that follows
its execution by both parties, and shall be automatically renewed for a period of 1 year on
January 1 each year thereafter, unless terminated under sections VIII (b) or (d) of this
Agreement, as described in 42 CFR § 423.2345.

(b) As described in 42 CFR § 423.2345(a), the Secretary may terminate this Agreement for a
knowing and willful violation of the requirements of the Agreement or other good cause shown
in relation to the Manufacturer's participation in the Discount Program. The termination shall
not be effective earlier than 30 calendar days after the date of notice to the Manufacturer of such
termination. The Secretary shall provide the Manufacturer with an opportunity to cure any
ground for termination for cause or to show the Manufacturer is in compliance with Section II
within thirty (30) calendar days of the Manufacturer’s receipt of the written termination notice.
If the Manufacturer cures the violation, or establishes that it was in compliance within the cure
period, the Secretary shall repeal the termination notice by written notice.

(c) As described in 42 CFR § 423.2345(a)(4) and (5), the Secretary shall provide, upon request,
a Manufacturer a hearing with a hearing officer concerning such termination if requested in
writing within 15 calendar days of receiving notice of the termination, and such hearing shall
take place prior to the effective date of the termination with sufficient time for such effective
date to be repealed if the Secretary determines appropriate. If the Manufacturer or CMS receives
an unfavorable decision from the hearing officer, the Manufacturer or CMS may request review
by the CMS Administrator. The decision of the CMS Administrator is final and binding.

(d) The Manufacturer may terminate this Agreement for any reason. Any such termination shall
be effective as of the day after the end of the calendar year if the termination occurs before
January 30 of a calendar year or as of the day after the end of the succeeding calendar year if the
termination occurs on or after January 30 of a calendar year, as described in 42 CFR § 423.2345(b).

(e) Any termination shall not affect the Manufacturer’s responsibility to reimburse Part D sponsors for applicable discounts for applicable drugs having NDCs with the Manufacturer’s FDA-assigned labeler codes that were incurred under the Agreement before the effective date of its termination, as described in 42 CFR § 423.2345(c).

(f) In accordance with 42 CFR § 423.2345(d), upon the effective date of the termination of this Agreement, CMS will cease releasing data to the Manufacturer under this Agreement, except as necessary to ensure that the Manufacturer reimburses applicable discounts for previous time periods in which the Agreement was in effect, and will notify the Manufacturer to destroy the data file(s) described in section VII of this Agreement. The provisions of sections IV, VI, and VII shall survive termination of this Agreement.

(g) Manufacturer reinstatement will be available only upon payment of any and all outstanding applicable discounts incurred during any previous period of the Agreement. The timing of any such reinstatement will be consistent with the requirements for entering into an Agreement under section 1860D-14A(b)(1)(C) of the Act and 42 CFR § 423.2345(e).

IX. GENERAL PROVISIONS

(a) Any notice required to be given pursuant to the terms and provisions of this Agreement will be sent in writing.

1. Notice to the Secretary will be sent to:

   Center for Medicare

   Division of Part D Policy
Mailstop C1-26-16
7500 Security Boulevard
Baltimore, MD 21244-1850

2. The CMS address may be updated upon written notice to the Manufacturer.

3. Notices to the Manufacturer will be sent to the address as provided with this Agreement and updated upon Manufacturer notification to CMS at the address in this Agreement.

(b) In the event of a transfer in ownership of the Manufacturer, this Agreement is automatically assigned to the new owner, and all terms and conditions of this Agreement remain in effect.

(c) Nothing in this Agreement will be construed to require or authorize the commission of any act contrary to law. If any provision of this Agreement is found to be invalid by a court of law with competent jurisdiction, this Agreement will be construed in all respects as if any invalid or unenforceable provision were eliminated, and without any effect on any other provision.

(d) Nothing in this Agreement shall be construed as a waiver or relinquishment of any legal rights of the Manufacturer or the Secretary under the Constitution, the Act, other Federal laws, or State laws.

(e) This Agreement shall be construed in accordance with Federal law and ambiguities shall be interpreted in the manner which best effectuates the statutory scheme. Any litigation arising from or relating to this Agreement shall be resolved in Federal court.

(f) The terms “Medicare” and “Manufacturer” incorporate any contractors which fulfill responsibilities pursuant to the Agreement unless specifically provided for in this Agreement.

(g) Except for the conditions specified in paragraph (a) of this section, this Agreement once finalized, will not be altered by the parties. However, the Secretary retains the authority to
amend the model Agreement after consulting with manufacturers and allowing for comment on such amendments.

(h) Nothing in this Agreement shall be construed as requiring coverage under Part D of a Manufacturer’s product if that product does not otherwise meet the definition of a covered Part D drug under 42 CFR § 423.100.

(i) Neither party shall be liable for failure to perform its obligations under this Agreement if such failure is occasioned by a contingency beyond such party’s reasonable control, including, but not limited to, lockouts, riots, wars, fires, floods or storms (a “Force Majeure Event”). A party claiming a right to excused performance under this section shall promptly notify the other party in writing to the extent of its inability to perform, which notice shall specify the Force Majeure Event that prevents such performance and include a timeline for remediation. The party failing to perform shall use reasonable efforts to avoid or remove the cause of the Force Majeure Event and shall resume performance under the Agreement promptly upon the cessation of the Force Majeure Event.

(j) This Agreement and the exhibits attached hereto contain the entire agreement of the parties with respect to the subject matter of this Agreement, and supersede all prior negotiations, agreements, and understandings with respect thereto.
X. SIGNATURES

FOR THE SECRETARY OF HEALTH AND HUMAN SERVICES

By: _________________________  _____________________________________
    (please print name)      (signature)
Title: _____________________________________________
Date:  ____________________________________________

FOR THE MANUFACTURER

A. By signing this Agreement, the Manufacturer agrees to abide by all provisions set out in this Agreement and acknowledges having received notice of potential criminal or administrative penalties for violation of the terms of the Agreement.

B. On behalf of the Manufacturer the undersigned individual hereby attests that he or she is authorized to legally bind the Manufacturer to the terms of this Agreement and agrees to all the terms specified herein.

I certify that I have made no alterations, amendments or other changes to this Medicare Coverage Gap Discount Program Agreement.

By: __________________________                        ____________________________________
    (please print name)    (signature)

Title:  _______________________________________
P#__________________
Name of Manufacturer:  _________________________________________
Manufacturer’s Mailing Address:  ______________________________________________
Exhibit A

MEDICARE PART D DISCOUNT INFORMATION DATA ELEMENTS

1. Date of Service
2. Service Provider Identifier Qualifier
3. Service Provider Identifier
4. Prescription/Service Reference Number
5. Product/Service Identifier
6. Quantity Dispensed
7. Days Supply
8. Fill Number
9. Reported Gap Discount
Exhibit B

PDE DATA ELEMENTS AVAILABLE UPON AUDIT ONLY

1. Contract Number
2. Plan Benefit Package Identifier
3. Ingredient Cost Paid
4. Dispensing Fee Paid
5. Total Amount Attributed to Sales Tax
6. Low-Income Cost Sharing Amount
7. Non-covered Plan Paid Amount
8. Vaccine Administration Fee
9. Total Gross Covered Drug Cost Accumulator
10. True Out-of-Pocket Accumulator

Exhibit C

DATA USE PROVISIONS

(a) PURPOSE

CMS agrees to provide the Manufacturer with certain data that reside in the Drug Data Processing System (DDPS), an established CMS Privacy Act System of Records. In exchange, the Manufacturer agrees 1) to ensure the integrity, security, and confidentiality of the data by complying with the terms of this Agreement and applicable law, including the Privacy Act and the Health Insurance Portability Accountability Act; and 2) to use the prescription or claim-level data only for purposes of evaluating the accuracy of claimed discounts and resolving disputes.
concerning the Manufacturer’s payment obligations under the Discount Program as described in
the applicable statutes, regulations, and this Agreement.

The following provisions address the conditions under which CMS will disclose and the
Manufacturer will obtain and use the CMS data file(s) specified in subsection (b)(1) of this
section and/or any derivative file(s) that can be used in concert with other information to identify
individuals. These provisions supplement any and all agreements between the parties with
respect to the use of data from the files specified in subsection (b)(1).

(b) MANUFACTURER’S RESPONSIBILITIES CONCERNING AND LIMITATIONS ON
USE OF DISCOUNT INFORMATION

1. The CMS data file(s) covered under this Agreement shall be referred to as “Medicare Part D
Discount Information” as defined in section I (k) of this Agreement and shall also include any
data provided by CMS or the TPA to the Manufacturer in support of the resolution of payment
disputes and audits pursuant to section V of this Agreement (hereinafter referred to as “Discount
Information”).

2. The Manufacturer agrees to limit the use of the Discount Information to those uses necessary
to evaluate the accuracy of claimed discounts and resolve disputes concerning the
Manufacturer’s payment obligations under the Discount Program. The Manufacturer may not
use the Discount Information to perform any functions not governed by this Agreement,
including but not limited to non-Coverage Gap Discount payments to Part D sponsors and their
subcontractors, payments to other providers of health and drug benefits under any Federal health
care program and marketing activities. These restrictions do not apply to the use of aggregated,
summary-level data (i.e. not prescription or claim-level data) for financial statement forecasting and accounting purposes.

3. The parties mutually agree that CMS retains all ownership rights to the data file(s) referred to in this Agreement, and that the Manufacturer does not obtain any right, title, or interest in any of the data furnished by CMS.

4. The Manufacturer agrees not to disclose, use or reuse the data covered by this Agreement, including data derived from data covered by this Agreement, except as specified in this Agreement or except as CMS shall authorize in guidance it issues in writing related to the administration of the Discount Program or as otherwise required by law. The Manufacturer further agrees not to, sell, rent, lease, loan, or otherwise grant access to the data covered by this Agreement, with the exception that the Manufacturer may grant access to such data to contracted third parties for purposes of assisting the Manufacturer in evaluating the accuracy of claimed discounts, resolving disputes, and otherwise exercising its rights and responsibilities under the Agreement so long as such contracted third parties are subject to the same confidentiality requirements set forth in this Agreement and that the Manufacturer maintains responsibility for ensuring compliance by these third parties with the confidentiality requirements of this Agreement.

5. The Manufacturer agrees that, within the Manufacturer’s organization and the organizations of its agents, access to the data covered by the Agreement shall be limited to the minimum amount of data necessary and minimum number of individuals who need access to the data for permitted activities such as those described under paragraphs 2 and 4 above. (i.e., individual’s access to the data will be on a need-to-know basis).

6. The parties mutually agree that the aforesaid files(s) (and/or any derivative file(s)), including
those files that directly identify proprietary or confidential information of a Part D sponsor or its subcontractors or affiliates and those files that can be used in concert with other information to identify individuals), may be retained by the Manufacturer for a period of ten (10) years from the date of payment of the invoice, hereinafter known as the “Retention Period.” The Manufacturer agrees to maintain, and provide upon request to CMS, written documentation of the regular destruction of the files within the required timeframe. The Manufacturer may retain the data beyond the ten year timeframe if the data is the subject of an unresolved audit, government investigation, or litigation, or if required by another applicable law and the Manufacturer notifies the Secretary of such matter and promptly destroys the data once the pending matter is resolved.  

7. The Manufacturer agrees to establish appropriate administrative, technical, and physical safeguards to protect the confidentiality of the data and to prevent unauthorized use or access to it. Further, the Manufacturer (or a contracted third party) agrees that the data must not be physically moved, transmitted or disclosed in any way from or by any site(s) owned, operated, or otherwise controlled by the Manufacturer (or the contracted third party) to any sites outside of the control of the Manufacturer (or the contracted third party) without written approval from CMS unless such movement, transmission or disclosure is required by a law.

8. The Manufacturer agrees to grant access at its facilities to the data to authorized representatives of CMS or DHHS Office of the Inspector General for the purpose of inspecting to confirm compliance with the terms of this Agreement upon reasonable notice and during normal business hours.

9. The Manufacturer agrees that it shall not attempt to link records included in the file(s) specified in subsection (b) 1 to any individually identifiable source of information. This includes attempts to link the data to other CMS data file(s) except that Manufacturers may link to
Discount Program data from prior quarters in order to validate that a claim has not been duplicated or that retroactive adjustments have been made. CMS may establish through guidance issued separately to the Manufacturer exceptions to this prohibition that may be necessary for purposes of the administration of the Discount Program.

10. In the event that a Manufacturer inadvertently receives individually identifiable information, the Manufacturer will report the incident to the CMS Action Desk by telephone at (410) 786-2580 or by e-mail notification at cms_it_service_desk@cms.hhs.gov within one hour of the Manufacturer’s discovery of the incident. The Manufacturer agrees not to disclose, use or reuse such data or information and acknowledges that the use of unsecured telecommunications, including the Internet, to transmit individually identifiable or deducible information derived from the file(s) specified in subsection (b)(1) is prohibited.

11. The Manufacturer agrees that in the event CMS determines or has a reasonable belief that the Manufacturer has made or may have made a use, reuse or disclosure of the aforesaid file(s) that is not authorized by this Agreement, CMS, at its sole discretion, may require the Manufacturer to: (a) promptly investigate and report to CMS the Manufacturer’s determinations regarding any alleged or actual unauthorized use, reuse or disclosure, (b) promptly resolve any problems identified by the investigation; (c) if requested by CMS, submit a formal response to an allegation of unauthorized use, reuse or disclosure; (d) if requested by CMS, submit a corrective action plan with steps designed to prevent any future unauthorized uses, reuses or disclosures; and (e) if requested by CMS, return data files to CMS or destroy the data files it received from CMS under this agreement. The Manufacturer understands that as a result of CMS’s determination or reasonable belief that unauthorized uses, reuses or disclosures have taken place, CMS may refuse to release further CMS data to the Manufacturer for a period of time to be
determined by CMS.

12. The Manufacturer agrees to report any breach of any information from the CMS data file(s), loss of these data or disclosure to any unauthorized persons to the CMS Action Desk by telephone at (410) 786-2580 or by e-mail notification at cms_it_service_desk@cms.hhs.gov within one hour of the Manufacturer’s discovery of the incident and to cooperate fully in the federal security incident process. While CMS retains all ownership rights to the data file(s), as outlined above, the Manufacturer shall bear the cost and liability for any breaches of the data file(s) while they are entrusted to the Manufacturer.

13. The Manufacturer hereby acknowledges that criminal penalties under § 1106(a) of the Social Security Act (42 U.S.C. § 1306(a)), including a fine not exceeding $10,000 or imprisonment not exceeding 5 years, or both, may apply to disclosures of information that are covered by § 1106 and that are not authorized by regulation or by Federal law. The Manufacturer further acknowledges that criminal penalties under the Privacy Act (5 U.S.C. § 552a(i)(3)) may apply if it is determined that the any individual employed or affiliated with the Manufacturer knowingly and willfully obtained the file(s) under false pretenses. Any person found to have violated sec. (i)(3) of the Privacy Act shall be guilty of a misdemeanor and fined not more than $5,000.

Finally, the Manufacturer acknowledges that criminal penalties may be imposed under 18 U.S.C. § 641 if it is determined that the Manufacturer, or any individual employed or affiliated therewith, has taken or converted to his own use data file(s), or received the file(s) knowing that they were stolen or converted. Under such circumstances, they shall be fined under Title 18 or imprisoned not more than 10 years, or both; but if the value of such property does not exceed the sum of $1,000, they shall be fined under Title 18 or imprisoned not more than 1 year, or both.